Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Acute Respiratory Distress Syndrome Clear all
Terminated Phase 1 Interventional Results available

Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)

NCT05027815
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Interventions
Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 11, 2026, 8:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

NCT05164744
View directory record Official record
Conditions
COVID-19 Pneumonia, COVID-19, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Lower Respiratory Infection, COVID-19 Acute Bronchitis, Coronavirus Disease 2019
Interventions
Cardiac MRI, Echocardiogram, 6-minute walk test, Questionnaire
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 11, 2026, 8:59 AM EDT
Not listed Phase 2 Interventional

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

NCT04905836
View directory record Official record
Conditions
Covid19
Interventions
COVI-MSC, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Brandon, Florida • Sarasota, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated Not applicable Interventional Results available

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NCT04382391
View directory record Official record
Conditions
COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions
gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 11, 2026, 8:59 AM EDT
Not listed No phase listed Observational

Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19

NCT05228717
View directory record Official record
Conditions
Lung Injury, ARDS, Acute Cardiac Event, Covid19, Ultrasound, Hypoxemia, Acute Respiratory Distress Syndrome
Interventions
Point of Care Ultrasound
Diagnostic Test
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Sylmar, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 11, 2026, 8:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

NCT04311697
View directory record Official record
Conditions
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
Drug
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 100 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

NCT04537806
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
Brexanolone, Placebo
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Fresno, California • Augusta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 11, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS

NCT04325906
View directory record Official record
Conditions
Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
Interventions
high flow nasal cannula (HFNC), Prone positioning (PP)
Device · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 11, 2026, 8:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform

NCT04663776
View directory record Official record
Conditions
Covid19, Influenza, Respiratory Tract Infections, Acute Respiratory Tract Infection, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated No phase listed Observational

Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery

NCT05258617
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome
Interventions
LLLT Photobiomodulation
Device
Lead sponsor
Ward Photonics LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Berkeley, California • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

NCT04402840
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
Stellate Ganglion Block
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 11, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)

NCT04581811
View directory record Official record
Conditions
ARDS, Covid19, Acute Hypoxemic Respiratory Failure
Interventions
Prolonged Proned Positioning, Traditional Proning Arm
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 11, 2026, 8:59 AM EDT
Withdrawn Phase 2 Interventional

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

NCT04728698
View directory record Official record
Conditions
Covid19, ARDS
Interventions
COVI-MSC, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 11, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 11, 2026, 8:59 AM EDT
Completed No phase listed Observational

Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)

NCT04383730
View directory record Official record
Conditions
Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
Interventions
Intravenous sedation, Inhaled sedation
Drug
Lead sponsor
University Hospital, Clermont-Ferrand
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 11, 2026, 8:59 AM EDT
Recruiting Phase 2 Interventional

Clazakizumab vs. Placebo - COVID-19 Infection

NCT04494724
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 11, 2026, 8:59 AM EDT
Withdrawn Phase 1 Interventional

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

NCT04574869
View directory record Official record
Conditions
Acute Lung Injury, ALI, COVID-19
Interventions
RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated Phase 4 Interventional

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

NCT04397510
View directory record Official record
Conditions
Covid-19, ARDS, Human, Acute Lung Injury
Interventions
Heparin, 0.9% Sodium-chloride
Drug
Lead sponsor
Frederick Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 11, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

NCT04842747
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
VERU-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 11, 2026, 8:59 AM EDT
Terminated No phase listed Observational

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection

NCT04356443
View directory record Official record
Conditions
Respiratory Failure, Ventilatory Failure, COVID-19, Pneumonia, ARDS, Human
Interventions
AirGo Respiratory Monitor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 11, 2026, 8:59 AM EDT